At the news
? NEUTRALIMPACT 4/10 8-K filed Aug 6, 2026 at 07:12 ET
Sionna Therapeutics reported Q2 2026 financial results with a net loss of $29.9M ($-0.66/share), wider than the $18.1M loss in Q2 2025, driven by increased R&D and G&A spending. The filing is a routine quarterly update for a pre-revenue clinical-stage biotech, with no new clinical data or guidance changes, both key pipeline trials remain on track for topline data this summer. Cash burn continues as expected, with $268.3M in cash funding operations into 2028, making this a neutral event with no material surprise vs expectations.
- Net loss of $29.9M for Q2 2026 vs $18.1M in Q2 2025, driven by higher R&D ($21.9M vs $15.4M) and G&A ($10.6M vs $6.5M) expenses.
- Cash, cash equivalents, and marketable securities totaled $268.3M as of June 30, 2026, expected to fund operations into 2028.
- PreciSION CF Phase 2a trial of SION-719 and Phase 1 dual combination trial of SION-451 both remain on track for topline data in summer 2026.
- EPS of $-0.66 for Q2 2026 vs consensus estimate of $-0.64 (a 3.1% miss).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access